Brief: Theratechnologies Initiates Basket Portion Of Th1902 First-In-Human Study In Advanced Resistant Malignancies
10/05/2022 12:33
May 10 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES INITIATES BASKET PORTION OF TH1902
FIRST-IN-HUMAN STUDY IN ADVANCED RESISTANT MALIGNANCIES
* THERATECHNOLOGIES INC - EXPANSION STUDY WILL EVALUATE
TH1902 IN
SOLID TUMORS WITH HIGH EXPRESSION OF SORTILIN RECEPTOR
Source text for Eikon: ID:nGNX4PP4Kb
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process